Affiliation:
1. Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas, USA
Abstract
Abstract
Camptothecin analogs, agents that target the intranuclear enzyme topoisomerase I, represent a promising new class of anticancer drugs for the treatment of childhood cancer. In preclinical studies, camptothecins, such as topotecan and irinotecan, are highly active against a variety of pediatric malignancies including neuroblastomas, rhabdomyosarcomas, gliomas, and medulloblastomas. In this paper, we review the status of completed and ongoing clinical trials and pharmacokinetic studies of camptothecin analogs in children. These and future planned studies of this novel class of cytotoxic agents are critical to defining the ultimate role of topoisomerase I poisons in the treatment of childhood cancer.
Publisher
Oxford University Press (OUP)
Reference90 articles.
1. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata;Wall;J Am Chem Soc,1966
2. Camptothecin. Discovery to clinic;Wall;Ann N Y Acad Sci,1996
3. Mechanistic aspects of DNA topoisomerases;Maxwell;Adv Protein Chem,1986
4. Characterization of structural features of camptothecin essential for topoisomerase I interaction and for induction of protein-linked DNA breaks in cells;Hertzberg;Proc Am Assoc Cancer Res,1987
5. An overview of topoisomerase I-targeting agents;Arbuck;Semin Hematol,1998
Cited by
42 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献